PharmaCyte increases TNF Pharmaceuticals stake by $3 million

PharmaCyte Biotech Inc. (NASDAQ: PMCB) announced it increased its investment in TNF Pharmaceuticals (NASDAQ: TNFA) by $3 million to support TNF's recent licensing agreement with LightSolver Ltd.

The license covers LightSolver's processing accelerator technology, which uses light for computation and is designed for cryptocurrency mining and blockchain applications. The technology claims to reduce energy consumption by 90% while providing faster processing speeds than conventional graphics processing units, quantum computing, and high-performance computing systems.

LightSolver was named a 2025 World Economic Forum Technology Pioneer and recognized in Gartner's 2025 Hype Cycle for Data Center Infrastructure Technologies. TNF expects to change its name and ticker symbol to reflect its new strategic direction.

PharmaCyte reported total assets of over $55 million as of April 30, 2025, and stated it continues to evaluate additional investment opportunities to expand and diversify its portfolio.

The information is based on a company press release statement.

You May Also Be Interested In

• First Advantage to join S&P SmallCap 600, replacing Kennedy-Wilson
• Lightwave Logic, Inc. (LWLG) files mixed shelf
• NVIDIA sets annual stockholder meeting for June 24